CyFlow CD138 PerCP
品番 | CU500436 | ||
---|---|---|---|
抗体名 | Anti-Hu CD138 PERCP,B-A38 | ||
包装単位 | 100 tests | ||
濃度 | - | ||
容量 | 1 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG1 PerCP (AH500793) |
||
反応性|交差吸着 | Human | レーザー | Blue, Green |
抗原 | CD138, Syndecan-1, B-B4 | 最大蛍光波長 | 678 nm |
クローン | B-A38 | 最大励起波長 | 482 to 490 nm |
ホスト | Mouse | 標識/Format | PerCP |
アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD138 PERCP,B-A38
特異性
The mouse monoclonal antibody B-A38 recognizes CD138 antigen, a 65-70 kDa heparan sulfate proteoglycan expressed mainly in the epidermis and plasma cells, but also in growth factor-stimulated lymphocytes.
抗原情報
CD138 (syndecan 1) is a transmembrane proteoglycan that can bind a variety of cytokines and modulate their activity, as well as the activity of extracellular matrix components and influence many developmental processes. CD138 is expressed mainly in differentiating keratinocytes and is transiently upregulated in all layers of the epidermis upon tissue injury. It is also highly expressed on plasma cells and can be detected even on fibroblasts, vascular smooth muscle cells and endothelial cells. Up-regulation and down-regulation of CD138 on the cell surface often correlates with the gain of cancerous characteristics. Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC: G1P3, an IFN‑induced survival factor, antagonizes TRAIL‑induced apoptosis in human myeloma cells. J·Clin·Invest. 2007·Oct; 117(10):3107‑17. <·PMID:·17823654·>
• Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, Min CK: Syndecan‑1, a key regulator of cell viability in endometrial cancer. Int·J·Cancer. 2007·Aug·15; 121(4):741‑50. <·PMID:·17455248·>
• Hayashida K, Johnston DR, Goldberger O, Park PW: Syndecan‑1 expression in epithelial cells is induced by transforming growth factor beta through a PKA‑dependent pathway. J·Biol·Chem. 2006·Aug·25; 281(34):24365‑74. <·PMID:·16807246·>
• Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M: Soluble syndecan‑1 (sCD138 as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int·J·Lab·Hematol. 2009·Feb; 31(1):97‑105. <·PMID:·18190591·>
• Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, Ettinger R: Essential role of IL‑21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell‑B cell collaboration. J·Immunol. 2007·Nov·1; 179(9):5886‑96. <·PMID:·17947662·>
• Manakil JF, Seymour GJ, Bartold PM: Effect of cytokine and antigen stimulation on peripheral blood lymphocyte syndecan‑1 expression. Oral·Microbiol·Immunol. 2007·Aug; 22(4):272‑6. <·PMID:·17600540·>
• Muto T, Miyoshi K, Munesue S, Nakada H, Okayama M, Matsuo T, Noma T: Differential expression of syndecan isoforms during mouse incisor amelogenesis. J·Med·Invest. 2007·Aug; 54(3‑4):331‑9. <·PMID:·17878683·>
• Ojeh N, Hiilesvuo K, Wärri A, Salmivirta M, Henttinen T, Määttä A: Ectopic expression of syndecan‑1 in basal epidermis affects keratinocyte proliferation and wound re‑epithelialization. J·Invest·Dermatol. 2008·Jan; 128(1):26‑34. <·PMID:·17625591·>
• Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD: The syndecan‑1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 2007·Sep·15; 110(6):2041‑8. <·PMID:·17536013·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN